Vivozon Pharmaceutical Co., Ltd. Stock: price and insider trades · South Korea
비보존 제약
No insider purchase over the last 90 days. The latest, by 비보존, was filed 07 May 2026.
Vivozon Pharmaceutical Co., Ltd.: what insiders have been doing
Vivozon Pharmaceutical Co., Ltd. is a Health Care company. Its directors and officers file their transactions with DART (FSS). Between 1 November 2025 and 1 November 2026, 15 insiders published 49 filings.
On the market, 15 insiders bought (31 purchases totalling €3.4M) while 2 insiders sold (6 sales totalling €314k). The totals exclude 24 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a purchase of €1.4M by 비보존, published on 7 May 2026, equal to 1.2% of the market capitalisation. Among those who bought: 6 board members, 6 senior executives and 1 major shareholder.
Compared with its exchange (2,655 companies, median 7 filings), a count of 49 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed 57 purchases and 9 sales.
In the case of 10 purchases, another manager of the company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. The clock since the last published purchase (7 May 2026) now reads 185 days. Typically, a trade is published a median of 7 days after it takes place. This delay matters because a trade only becomes useful information once it is public.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySale+9 other insiders
Since the insiders bought
- +0.7%Entry ₩3,075 · Close 30 Oct 2026 ₩3,095
- -3.0%Entry ₩3,190 · Close 30 Oct 2026 ₩3,095
- -3.0%Entry ₩3,190 · Close 30 Oct 2026 ₩3,095
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 277,778 sharesShareKRXDART:20260807000146
- ●Executives0DART
- KRXDART:20260701000010
- ●Executives0DART
- ●Executives0DART
- 277,778 sharesKRXDART:20260526000366
- 277,778 shares@ ₩9,000.001.19% mcap100.0% of flowShareKRXDART:20260507000560Canonical exit: 29 Jul 2026 (T+90)
- 2,000 sharesShareKRXDART:20260415000508Canonical exit: 14 Jul 2026 (T+90)
- 5,919 sharesShareKRXDART:20260415000525Canonical exit: 14 Jul 2026 (T+90)
- 180,954 shares0.26% mcap24.6% of flowKRXDART:20260409002937
- 11,674 sharesShareKRXDART:20260406003902Canonical exit: 29 Jun 2026 (T+90)
- 180,954 shares@ ₩9,000.000.77% mcap100.0% of flowShareKRXDART:20260403003027Canonical exit: 29 Jun 2026 (T+90)
- 0KRXDART:20260331003925
- 0KRXDART:20260323001067
- 6,694 shares@ ₩3,065.000.0053% mcap100.0% of flowShareKRXDART:20260312000416Canonical exit: 3 Jun 2026 (T+90)
- 1,067,850 shares@ ₩3,065.000.79% mcap75.4% of flowShareKRXDART:20260312000892Canonical exit: 3 Jun 2026 (T+90)
- 30,232 shares@ ₩3,065.000.024% mcap100.0% of flowShareKRXDART:20260312000316Canonical exit: 3 Jun 2026 (T+90)
- 3,531 shares@ ₩3,065.000.0019% mcap100.0% of flowShareKRXDART:20260312001284Canonical exit: 3 Jun 2026 (T+90)
- 938 shares@ ₩3,065.000.0007% mcap100.0% of flowShareKRXDART:20260312000131Canonical exit: 3 Jun 2026 (T+90)
- 452 shares@ ₩3,065.000.0004% mcap100.0% of flowShareKRXDART:20260312000032Canonical exit: 3 Jun 2026 (T+90)
25 of 111 declarations
About Vivozon Pharmaceutical Co., Ltd.
Vivozon Pharmaceutical is a biotechnology company focused on developing innovative drugs. It is listed on the XKRX market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
